ACW September 2025 quarterly activity report & Appendix 4C

Actinogen Medical is pleased to announce the release of its September 2025 quarterly activity report and Appendix 4C. Key highlights include the acceleration of enrolment in the XanaMIA phase 2b/3 AD trial, with an updated timeline for final results in mid Q4 2026. The interim analysis for the trial remains on-track for late January 2026. A successful meeting with the FDA on the Alzheimer's program and the completion of a clinical pharmacokinetic trial for Xanamem were achieved. The company launched its Investor Hub site to provide shareholders with key updates and encourage engagement through Q&A. Manufacturing progress was made with the import of drug substance to the US for scaled-up tablet production. Additionally, ongoing initiatives include commercial planning, partnering discussions, strengthening IP protection, and preparations for a phase 3 trial and ancillary clinical studies. Financially, the company received funding from the R&D tax incentive (RDTI) and maintains a cash runway to mid-2026. The Company has a proforma cash position of $12.4m and has the potential to access additional funding in the short to medium-term from exercise of unlisted (3.75 cents) and listed (5.00 cents) stock options, future co-development partnerships and borrowing against its FY26 RDTI.

Actinogen continues to focus on late-stage clinical development of oral Xanamem for Alzheimer's disease - designed to position Xanamem as the leading next-generation therapy in the field. The company encourages investors to visit the Investor Hub for more information and invites questions to engage with the leadership team.

To join a webinar discussing recent progress, upcoming milestones and participate in a live Q&A session please see the related announcement today or register via pasting this link into your browser: https://actinogenmedical.zoom.us/webinar/register/WN_L_TOuTmaR4qYvYnXrNzfDQ